Quarterly ResultMay 6, 2026, 04:22 PM
Lyell Immunopharma Q1 Net Loss Narrows to $24.15M; Raises $51.7M
AI Summary
Lyell Immunopharma reported a significantly reduced net loss of $24.15 million for the first quarter of 2026, compared to $52.20 million in the prior year. The company also strengthened its financial position by raising $51.72 million through equity issuances, including a $50 million PIPE financing. Additionally, Lyell acquired exclusive global rights to LYL273, a novel CAR T-cell product candidate for metastatic colorectal cancer, for an upfront payment of $40 million cash and 1.9 million shares. Management believes it has sufficient working capital to fund operations for at least the next 12 months.
Key Highlights
- Net loss for Q1 2026 narrowed to $24.15 million from $52.20 million in Q1 2025.
- Net loss per common share improved to $(1.10) in Q1 2026 from $(3.54) in Q1 2025.
- Research and development expenses decreased to $36.60 million from $43.45 million year-over-year.
- General and administrative expenses decreased to $9.56 million from $14.05 million year-over-year.
- Proceeds from equity issuances totaled $51.72 million, including a $50 million PIPE financing.
- Cash and cash equivalents increased to $90.77 million as of March 31, 2026.
- Acquired exclusive global rights to LYL273 for $40 million cash and 1.9 million shares.
- Management expects sufficient working capital to fund operations for at least 12 months.